تصفح حسب المؤلف "Elazzazy, Shereen"
-
A Review of Clinical Outcomes Associated with Two Meropenem Dosing Strategies
Wilby, Kyle John; Nasr, Ziad Ghantous; Elazzazy, Shereen; Lau, Tim T. Y.; Hamad, Anas ( Springer International Publishing , 2017 , Article Review)Meropenem is a carbapenem antibiotic that exhibits time-dependent bactericidal activity, traditionally dosed intravenously at 1�g every 8�h. In order to maximize its pharmacodynamic activity and reduce costs, an alternative ... -
Applying value-based strategies to accelerate access to novel cancer medications: guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP)
Hamad, Anas; Elazzazy, Shereen; Bujassoum, Salha; Rasul, Kakil; Gaziev, Javid; Cherif, Honar; Al-Boloshi, Zakiya; Hanssens, Yolande; Saleh, Ayman; Rasheed, Hadi Abu; Al-Badriyeh, Daoud; Babiker, Ahmed; Hmaidan, Amid Abu; Al-Hail, Moza... more authors ... less authors ( BioMed Central Ltd , 2023 , Article)Background: In line with global trends, cancer incidence and mortality may have decreased for specific types of cancer in Qatar. However, the cancer-related burden on patients, healthcare systems, and the economy is expected ... -
Clinical pharmacokinetics: perceptions of hospital pharmacists in Qatar about how it was taught and how it is applied
Kheir, Nadir; Awaisu, Ahmed; Gad, Hoda; Elazzazy, Shereen; Jibril, Farah; Gajam, Mawadda... more authors ... less authors ( Kluwer Academic Publishers , 2015 , Article)Background The application of clinical pharmacokinetics (PK) is essential when providing pharmaceutical care. Appropriate application of PK monitoring results in improved patient outcomes including decreased mortality, ... -
Cost-Effectiveness and Cost-Utility of Palbociclib versus Ribociclib in Women with Stage IV Breast Cancer: A Real-World Data Evaluation
Al-Ziftawi, Nour Hisham; Alam, Mohammed Fasihul; Elazzazy, Shereen; Shafie, Asrul Akmal; Hamad, Anas; Mohamed Ibrahim, Mohamed Izham... more authors ... less authors ( MDPI , 2022 , Article)Palbociclib and ribociclib are indicated in the first-line treatment of hormonal-receptor-positive HER-2 negative (HR+/HER-2 negative) advanced breast cancer. Despite their clinical benefit, they can increase healthcare ...